Signal active
Bio
Lanchun is a Managing Partner of Cathay Capital, based in Shanghai.
Lanchun joined Cathay Capital in 2010, and brings to the firm 10 years of audit and transaction services experience in China.
Prior to Cathay Capital, Lanchun was an Associate Director with Deloitte & Touch Corporate Finance in China. In her role, she led the financial review and valuation of M&A targets, and assisted with regulatory compliance and structures of deals, for many corporate and private equity firms. Representative clients included 3i, Blackstone, Carlyle, Merrill Lynch, SAIF Investment, Sumitomo, Shell, Iveco, Baosteel, China Resources, Jinjiang Group, Shanghai Auto Industrial Group.
Previously, Lanchun was an Assistant Business Manager of Brian Jessel BMW in Vancouver, Canada. Prior to that, and out of undergraduate school, Lanchun spent 3 years as a Senior Accountant at PricewaterhouseCoopers in Beijing, where she performed IPO audits for large Chinese companies.
Lanchun holds a bachelor degree in Accounting from the Central University of Finance and Economics in Beijing. She is also graduated from the Simon Fraser University Business School in Canada, and CEIBS in Shanghai (executive MBA).
Location
Shanghai, Shanghai, China, Asia
Social
N/A
Primary Organization
2015
130
54
12
11-50
Financial Services, Venture Capital, Finance
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Lanchun Duan is the Managing Partner at Cathay Innovation, based in Asia. With a background in Financial Services, Lanchun Duan has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
4
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Apr 07, 2021 | PackGene Biotech | Series C - PackGene Biotech | Cathay Capital | 0 |
Apr 24, 2023 | Weining Technology | Series C - Weining Technology | Cathay Capital | 43.5M |
Jan 08, 2024 | Huiying Medical | Series B - Huiying Medical | Cathay Capital | 14.1M |
Feb 21, 2024 | Bio-Link | Series A - Bio-Link | Cathay Capital | 0 |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.